Physician profile
Ashkan Emadi
NPI 1457562753
$88,241.28
in general payments reported to CMS, 2019-2025
16 companies · $5,103 in 2025
The $5,103 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $5,323 · 2021: $30K · 2022: $17K · 2023: $15K · 2024: $1,076 · 2025: $5,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Travel and Lodging: $1,841 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,000 · Food and Beverage: $893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,013.50 |
| Travel and Lodging | $1,840.76 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,000.00 |
| Food and Beverage | $893.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Secura Bio, INC. | $26,565.00 | 2021-2022 | |
| Amgen INC. | $21,597.25 | 2019-2025 | Lumakras, Blincyto, Blincyto |
| Kite Pharma, INC. | $15,950.00 | 2021-2022 | |
| Servier Pharmaceuticals LLC | $9,200.77 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $6,074.15 | 2019-2025 | |
| Genentech USA, INC. | $4,505.63 | 2019 | |
| Incyte Corporation | $2,818.00 | 2022 | |
| Celgene Corporation | $1,000.00 | 2023 | |
| Jazz Pharmaceuticals INC. | $368.67 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $103.85 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $35.10 | 2023 | Calquence |
| Daiichi Sankyo INC. | $22.86 | 2023 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashkan Emadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.